Health TrialsbyHealthPanel

The Clinical Research of Traditional Chinese Medicine Compound Formulas

ConditionsUrologic InjuriesUrology
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine

About this trial

To observe the efficacy and safety of Shenkangling, a traditional Chinese medicine decoction, for renal ischemia-reperfusion injury, and to provide evidence-based medical evidence and ideas for clinical therapeutic use.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Fulfillment of western medical diagnostic criteria requiring renal ischemia-reperfusion surgical operation and renal artery clamping time ≤ 30 min

Meets the criteria for Chinese medicine identification

18 ≤ age ≤ 65

Voluntary participation with signed informed consent

Disqualifiers

Patients with stage 4 or 5 renal insufficiency or patients with acute renal failure

Those with secondary factors such as systemic lupus erythematosus, drug-induced renal damage, etc. confirmed by examination

Does not meet the diagnosis of renal ischemia-reperfusion injury

Cases not within the scope of action of the drug

Trial design

Design model

Parallel

Treatments tested in this trial

  • Shenkangling

    Drug

    Chinese herbal tonics taken orally: Shenkangling, one dose, 2 times a day, 1 time before breakfast and 1 time 30 minutes after dinner.

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: control groupNo intervention 0 interventions
Group B: Shenkangling groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Rate of 24-hour urine protein excretion

Time frame
From enrollment to the end of treatment at 8 weeks
2

Levels of renal function

Biochemical tests for blood creatinine and urea nitrogen

Time frame
From enrollment to the end of treatment at 8 weeks
3

Specific gravity of urine

Time frame
From enrollment to the end of treatment at 8 weeks
4

blood viscosity

By measuring the flow rate of blood in capillaries to evaluate blood viscosity

Time frame
From enrollment to the end of treatment at 8 weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: